[Treatment of acute leukemias in adults. III. Analysis of 5 cases with survival over 21/2 years].
Out of 49 adult patients with acute leukaemia admitted successively over a period of 3 years (1976-1978) those surviving next 1.5 year were followed up (till June 30 1980). Forty-one cases were qualified for combined treatment with cytostatic drugs. Five patients are alive over 2.5 years (30-46 months), three of them in the first complete remission (28-33 months), one patient in second remission, and one patient is alive with relapse after first complete remission. The per cent of patients surviving over 2.5 years is 10.2% of the successively admitted patients, and 12.2% of those treated with cytostatic drugs. This fairly long survival may be due to intensive induction treatment and maintenance treatment.
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D003422:Critical Care / Q000379:methods; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007938:Leukemia / Q000188:drug therapy / Q000401:mortality*; D007945:Leukemia, Lymphoid / Q000188:drug therapy / Q000401:mortality; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D003561:Cytarabine; D014750:Vincristine; D003520:Cyclophosphamide; D015122:Mercaptopurine; D011241:Prednisone; D008727:Methotrexate; D003630:Daunorubicin
Leczenie ostrych białaczek u dorosłych III. Analiza pieciu przypadków przezycia ponad 2,5-letniego.